14.04.2021 Vivoryon Therapeutics N.V.  NL00150002Q7

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reschedules the Reporting of the Full Year 2020 Financial Results to April 30, 2021


 

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reschedules the Reporting of the Full Year 2020 Financial Results to April 30, 2021

14.04.2021 / 07:00
The issuer is solely responsible for the content of this announcement.


Vivoryon Therapeutics N.V. Reschedules the Reporting of the Full Year 2020 Financial Results to April 30, 2021


HALLE (SAALE) / MUNICH, GERMANY, 14 April 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) announced today that the publication of the Full Year 2020 financial results, which had been scheduled for April 20th, 2021, will be postponed until April 30th, 2021. The postponement is due to unexpected delays in the finalization of Vivoryon's financial statements related to its transition into a Dutch N.V. corporation. The Company's Board of Directors made the decision to move the reporting date to ensure completeness of the filing and in compliance with the laws of the Netherlands.
 

###


For more information, please contact:
Vivoryon Therapeutics N.V.
Dr. Ulrich Dauer, CEO
Email: [email protected]

Trophic Communications
Gretchen Schweitzer / Valeria Fisher
Tel: +49 172 861 8540 or +49 175 8041816
Email: [email protected]


About Vivoryon Therapeutics N.V.

With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon is advancing its lead product, varoglutamstat (PQ912), in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury. www.vivoryon.com


Forward Looking Statements

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics N.V. as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.



14.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Vivoryon Therapeutics N.V.
Weinbergweg 22
06120 Halle/Saale
Germany
Phone: +49 (0)345 555 9900
Fax: +49 (0)345 555 9901
E-mail: [email protected]
Internet: www.vivoryon.com
ISIN: NL00150002Q7
WKN: A2QJV6
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam
EQS News ID: 1184279

 
End of News DGAP News Service

1184279  14.04.2021 

fncls.ssp?fn=show_t_gif&application_id=1184279&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 0,00 0,00 0,00 0,00 0,00 10,76 0,00
EBITDA1,2 -13,67 -9,86 -7,68 -7,63 -15,87 -12,63 0,00
EBITDA-Marge3 0,00 0,00 0,00 0,00 0,00 -117,38 0,00
EBIT1,4 -13,77 -9,96 -7,70 -7,72 -16,01 -12,79 0,00
EBIT-Marge5 0,00 0,00 0,00 0,00 0,00 -118,87 0,00
Jahresüberschuss1 -13,89 -8,01 -7,74 -7,82 -16,51 -12,66 0,00
Netto-Marge6 0,00 0,00 0,00 0,00 0,00 -117,66 0,00
Cashflow1,7 -13,26 -12,12 -6,99 -11,61 -14,01 -11,26 0,00
Ergebnis je Aktie8 -1,82 -0,98 -0,94 -0,62 -0,83 -0,63 -0,51
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Vivoryon Therapeutics
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2QJV6 8,470 186,77
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -7,68
KBV KCV KUV EV/EBITDA
11,28 - 17,35 -13,77
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,00 0,00 0,00 22.06.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
25.06.2021 21.09.2021 04.11.2021 28.04.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-13,60% -44,80% -55,47% -36,98%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Vivoryon Therapeutics N.V.  ISIN: NL00150002Q7 können Sie bei DGAP abrufen


Biotechnologie , A2QJV6 , 05Y , XETR:PB9